These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 25818740

  • 21. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 22. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 24. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
    Mutlu H, Gündüz S, Karaca H, Büyükçelik A, Cihan YB, Erden A, Akca Z, Coşkun HS.
    Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
    [Abstract] [Full Text] [Related]

  • 25. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T, Itano H, Fukita S, Saitoh M, Takeda S.
    Intern Med; 2014 Aug; 53(20):2347-51. PubMed ID: 25318801
    [Abstract] [Full Text] [Related]

  • 26. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB, Ozturk A, Mutlu H.
    Asian Pac J Cancer Prev; 2014 Aug; 15(5):2061-7. PubMed ID: 24716935
    [Abstract] [Full Text] [Related]

  • 27. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.
    J Clin Oncol; 2003 Jul 15; 21(14):2636-44. PubMed ID: 12860938
    [Abstract] [Full Text] [Related]

  • 28. [Malignant pleural mesothelioma: 2013 state of the art].
    Campbell K, Brosseau S, Reviron-Rabec L, Bergot E, Lechapt E, Levallet G, Zalcman G.
    Bull Cancer; 2013 Dec 15; 100(12):1283-93. PubMed ID: 24225007
    [Abstract] [Full Text] [Related]

  • 29. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X, Jiang Z, Duan J.
    Zhongguo Fei Ai Za Zhi; 2022 Jan 20; 25(1):7-13. PubMed ID: 35078279
    [Abstract] [Full Text] [Related]

  • 30. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R, Caramanti M, Fiordoliva I, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Castagnani M, Rovinelli F, Onofri A, Cascinu S.
    Support Care Cancer; 2015 Mar 20; 23(3):621-6. PubMed ID: 25142706
    [Abstract] [Full Text] [Related]

  • 31. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
    Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA.
    Ann Oncol; 2015 Dec 20; 26(12):2483-90. PubMed ID: 26386124
    [Abstract] [Full Text] [Related]

  • 32. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.
    J Clin Oncol; 2019 Oct 01; 37(28):2537-2547. PubMed ID: 31386610
    [Abstract] [Full Text] [Related]

  • 33. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H, Meng Q, Li M, Shi L, Tang J, Liu Z.
    Thorac Cancer; 2018 Feb 01; 9(2):298-304. PubMed ID: 29297985
    [Abstract] [Full Text] [Related]

  • 34. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
    Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T.
    Med Oncol; 2013 Feb 01; 30(3):676. PubMed ID: 23925664
    [Abstract] [Full Text] [Related]

  • 35. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.
    Lung Cancer; 2012 Mar 01; 75(3):360-7. PubMed ID: 21937142
    [Abstract] [Full Text] [Related]

  • 36. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI, Khorshid O, Abo Elkasem F, Bahnassy A, Gaafer R.
    Asian Pac J Cancer Prev; 2023 Jan 01; 24(1):195-205. PubMed ID: 36708568
    [Abstract] [Full Text] [Related]

  • 37. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K.
    Clin Lung Cancer; 2018 Sep 01; 19(5):e705-e707. PubMed ID: 29853412
    [Abstract] [Full Text] [Related]

  • 38. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
    Nie K, Zhang Z, You Y, Zhuang X, Zhang C, Ji Y.
    Thorac Cancer; 2020 Jan 01; 11(1):8-14. PubMed ID: 31726490
    [Abstract] [Full Text] [Related]

  • 39. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P.
    J Thorac Oncol; 2016 May 01; 11(5):758-768. PubMed ID: 26845191
    [Abstract] [Full Text] [Related]

  • 40. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
    Rusch VW, Figlin R, Godwin D, Piantadosi S.
    J Clin Oncol; 1991 Feb 01; 9(2):313-9. PubMed ID: 1988578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.